Faculty ProfilesJulie Ishida, MD
521 Parnassus Avenue
San Francisco, CA 94117
College: University of California, Berkeley, BA in Molecular and Cell Biology/Biochemistry
Medical school: Stanford University, MD
Other graduate training: University of California, San Francisco, MAS in Clinical Research
Internal medicine residency: University of California, San Francisco
Nephrology fellowship: University of California, San Francisco
Dr. Ishida is establishing herself as a young investigator in patient-oriented clinical research aimed at improving the quality of medication prescribing for patients with kidney disease. Her work to date includes studies pertaining to medication safety in hemodialysis patients, and she is now focused on the development of a digital tool to optimize the prescription of analgesics in hemodialysis patients. Her long-term goal is to develop, implement and evaluate strategies to promote the appropriate use of medications, including analgesics, in patients with chronic kidney disease requiring and not requiring dialysis.
Education and Training
|Location||Degree or Training||Specialty||Date|
|University of California, San Francisco||M.A.S. in Clinical Research||Epidemiology & Biostatistics||2013|
|University of California, Berkeley||B.A.||Molecular and Cell Biology/Biochemistry||2001|
|University of California, San Francisco||Fellowship||Nephrology|
|University of California, San Francisco||Residency||Internal Medicine|
Awards and Honors
Mentored Patient-Oriented Research Career Development Award (K23), National Institute of Diabetes and Digestive and Kidney Diseases, 2015-2020
American Society of Nephrology Research Fellowship, American Society of Nephrology, 2012-2014
Pragmatic Clinical Trials Early Program Travel Support, American Society of Nephrology, 2011
Presidential Poster of Distinction, American Association for the Study of Liver Diseases, 2006
Doris Duke Charitable Foundation Clinical Research Fellowship, University of California, San Francisco, 2005-2006
Highest Distinction (equivalent to summa cum laude), UC Berkeley, 2001
Phi Beta Kappa, UC Berkeley, 2001
In the News
- IV Iron in Hospitalized Hemodialysis Patients Not Linked With Worsening Infections (Oct 21, 2015)
- Renal Fellow Network: Infections and Intravenous Iron (Sep 29, 2015)
- Data Challenge IV Iron Withholding Guideline (Nov 14, 2014)
- Dialysis Facility Profit Status and Compliance With a Black Box Warning (May 20, 2013)
- Warning didn't change for-profit dialysis drug use (May 16, 2013)
- AASLD: For Chronic HCV, Pour the Coffee But Hold the Pot (Oct 30, 2006)
|Project Title||Project Number||Fiscal Year|
|Facilitating Appropriate Analgesic Prescription in Hemodialysis Patients||K23DK103963||2020|
Ishida JH, Auer R, Vittinghoff E, Pletcher MJ, Reis JP, Sidney S, Johansen KL, Bibbins-Domingo K, Peralta CA, Shlipak MG. Marijuana Use and Estimated Glomerular Filtration Rate in Young Adults. Clin J Am Soc Nephrol. 2017 Aug 24.
Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B, Fouts AE, Maia M, Deng R, Rosenberger CM, Gennaro LA, Striano NS, Liao XC, Tavel JA. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrob Agents Chemother. 2016 Nov 21.
Ishida JH, Marafino BJ, McCulloch CE, Dalrymple LS, Dudley RA, Grimes BA, Johansen KL. Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection. Clin J Am Soc Nephrol. 2015 Oct 07; 10(10):1799-805.
Ishida JH, Burgess T, Derby MA, Brown PA, Maia M, Deng R, Emu B, Feierbach B, Fouts AE, Liao XC, Tavel JA. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Antimicrob Agents Chemother. 2015 Aug; 59(8):4919-29.
Ishida JH, Marafino B, McCulloch CE, Dalrymple LS, Dudley RA, Grimes BA, Johansen KL. J Am Soc Nephrol. Association between Intravenous Iron Receipt and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection (Oral presentation at American Society of Nephrology Annual Meeting 2014). 2014; 25:55A.
Dalrymple LS, Johansen KL, Romano PS, Chertow GM, Mu Y, Ishida JH, Grimes B, Kaysen GA, Nguyen DV. Comparison of hospitalization rates among for-profit and nonprofit dialysis facilities. Clin J Am Soc Nephrol. 2014 Jan; 9(1):73-81.
Dalrymple LS, Johansen KL, Romano PS, Chertow GM, Mu Y, Ishida JH, Grimes BA, Kaysen G, Nguyen DV. J Am Soc Nephrol. Comparison of Hospitalization between For-Profit and Nonprofit Dialysis Facilities (Oral presentation at American Society of Nephrology Annual Meeting 2013). 2013; 24:29A.
Ishida JH, McCulloch CE, Dudley RA, Grimes BA, Johansen KL. J Am Soc Nephrol. Change in Erythropoiesis-Stimulating Agent Dosage in For-profit versus Non-profit Dialysis Facilities after a Black Box Warning (Poster presentation at American Society of Nephrology Annual Meeting 2012). 2012; 23:420A.
Ishida JH, Jin C, Bacchetti P, Tan V, Peters MG, Terrault NA. Hepatology. Influence of Cannabis Use on Severity of Hepatitis C Disease (Poster presentation at American Association for the Study of Liver Diseases Annual Meeting 2006). 2006; 44(S1):268A.